FDA grants fast track designation for Priothera’s AML therapy
The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant